D-erythro-Sphingosine-d7
Based on 1 publication(s) in Google Scholar
D-erythro-Sphingosine-d7 is the deuterium labeled D-erythro-Sphingosine. D-erythro-Sphingosine (Erythrosphingosine) is a very potent activator of p32-kinase with an EC50 of 8 μM, and inhibits protein kinase C (PKC). D-erythro-Sphingosine (Erythrosphingosine) is also a PP2A activator.
For research use only. We do not sell to patients.
- Purity: 99.0%
- CAS No.: 1246304-34-6
- Formula: C18H30D7NO2
- Molecular Weight:306.54
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) D-erythro-Sphingosine-d7
MoreAll Endogenous Metabolite Isoforms
More
Biological Activity
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 1246304-34-6
-
Unlabeled Cas 123-78-4
-
Appearance Solid
-
Molecular Weight 306.54
-
Formula C18H30D7NO2
-
Color White to off-white
-
SMILES
[2H]C([2H])([2H])C([2H])([2H])C([2H])([2H])CCCCCCCCCC/C=C/[C@@H](O)[C@@H](N)CO
-
Synonyms
Erythrosphingosine-d7; erythro-C18-Sphingosine-d7; trans-4-Sphingenine-d7
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Chromatogr B Analyt Technol Biomed Life Sci
Simultaneous quantification of sphingolipid metabolites in human plasma using UPLC-MS/MS. [Abstract]2026 May 1:1275:125003. PMID: 41791259
Solvent & Solubility
DMSO : 50 mg/mL (163.11 mM; Need ultrasonic and warming; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (269 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
[2]. Pushkareva MYu, et al. Regulation of sphingosine-activated protein kinases: selectivity of activation by sphingoid basesand inhibition by non-esterified fatty acids. Biochem J. 1993 Sep 15;294 ( Pt 3):699-703. [Content Brief]
[3]. Khan WA, et al. Protein kinase C and platelet inhibition by D-erythro-Sphingosine: comparison with N,N-dimethylsphingosine and commercial preparation. Biochem Biophys Res Commun. 1990 Oct 30;172(2):683-91. [Content Brief]
[4]. Pham VT, et al. A concise synthesis of a promising protein kinase C inhibitor: D-erythro-Sphingosine. Arch Pharm Res. 2007 Jan;30(1):22-7. [Content Brief]
[5]. Cheng P, et al. Protein phosphatase 2A (PP2A) activation promotes axonal growth and recovery in the CNS. J Neurol Sci. 2015 Dec 15;359(1-2):48-56. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2622 mL | 16.3111 mL | 32.6222 mL | 81.5554 mL |
| 5 mM | 0.6524 mL | 3.2622 mL | 6.5244 mL | 16.3111 mL | |
| 10 mM | 0.3262 mL | 1.6311 mL | 3.2622 mL | 8.1555 mL | |
| 15 mM | 0.2175 mL | 1.0874 mL | 2.1748 mL | 5.4370 mL | |
| 20 mM | 0.1631 mL | 0.8156 mL | 1.6311 mL | 4.0778 mL | |
| 25 mM | 0.1305 mL | 0.6524 mL | 1.3049 mL | 3.2622 mL | |
| 30 mM | 0.1087 mL | 0.5437 mL | 1.0874 mL | 2.7185 mL | |
| 40 mM | 0.0816 mL | 0.4078 mL | 0.8156 mL | 2.0389 mL | |
| 50 mM | 0.0652 mL | 0.3262 mL | 0.6524 mL | 1.6311 mL | |
| 60 mM | 0.0544 mL | 0.2719 mL | 0.5437 mL | 1.3593 mL | |
| 80 mM | 0.0408 mL | 0.2039 mL | 0.4078 mL | 1.0194 mL | |
| 100 mM | 0.0326 mL | 0.1631 mL | 0.3262 mL | 0.8156 mL |
D-erythro-Sphingosine-d7 Related Classifications
HY-101047S Related Classifications
Powered by Bioz